Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breather Plus short-cycle dolutegravir-based ART in adolescents with HIV in sub-Saharan Africa
ISRCTN85058577Phase 3Completed
- Sponsor
- University College London
- Start
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of dolutegravir, tenofovir, lamivudine and emtricitabine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University College London. Primary endpoint: Confirmed virological rebound by week 96. Started Jun 2022; status: completed.
02
Drugs
dolutegravirtenofovirlamivudineemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN85058577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85058577.